<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01434472</url>
  </required_header>
  <id_info>
    <org_study_id>2398.00</org_study_id>
    <secondary_id>NCI-2011-01189</secondary_id>
    <secondary_id>2398.00</secondary_id>
    <secondary_id>P01CA044991</secondary_id>
    <secondary_id>P30CA015704</secondary_id>
    <secondary_id>RG9213033</secondary_id>
    <nct_id>NCT01434472</nct_id>
  </id_info>
  <brief_title>High-Dose Y-90-Ibritumomab Tiuxetan Added to Reduced-Intensity Allogeneic Stem Cell Transplant Regimen for Relapsed or Refractory Aggressive B-Cell Lymphoma</brief_title>
  <official_title>A Phase II Trial of High-Dose 90Y-Ibritumomab Tiuxetan (Anti-CD20) Followed by Fludarabine and Low-Dose Total Body Irradiation and HLA-Matched Allogeneic Hematopoietic Transplantation for Patients With Relapsed or Refractory Aggressive B-Cell Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fred Hutchinson Cancer Research Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Fred Hutchinson Cancer Research Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase II trial studies the side effects and how well high-dose yttrium-90&#xD;
      (Y-90)-ibritumomab tiuxetan (anti-cluster of differentiation [CD]20) followed by fludarabine&#xD;
      phosphate, low-dose total body irradiation (TBI), and donor peripheral blood stem cell&#xD;
      transplant (PBSCT) work in treating patients with aggressive B-cell lymphoma that has&#xD;
      returned after a period of improvement (relapsed) or has not responded to previous treatment&#xD;
      (refractory). Radiolabeled monoclonal antibodies, such as Y-90-ibritumomab tiuxetan, can find&#xD;
      cancer cells and carry cancer-killing substances to them with less effect on normal cells.&#xD;
      Giving chemotherapy, such as fludarabine phosphate, and TBI before a donor PBSCT helps stop&#xD;
      the growth of cancer cells. It may also stop the patient's immune system from rejecting the&#xD;
      donor's stem cells. However, high-dose radiolabeled antibodies also destroy healthy blood&#xD;
      cells in the patient's body. When healthy stem cells from a donor are infused into the&#xD;
      patient (stem cell transplant), they may help the patient's body replace these blood cells.&#xD;
      Giving high-dose Y-90-ibritumomab tiuxetan followed by fludarabine phosphate, TBI, and donor&#xD;
      PBSCT may be an effective treatment for patients with B-cell lymphoma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:&#xD;
&#xD;
      I. To assess the safety and efficacy of 1.5 mCi/kg (max 120 mCi) 90Y-Ibritumomab tiuxetan&#xD;
      (yttrium Y 90 ibritumomab tiuxetan) (anti-CD20) combined with fludarabine (fludarabine&#xD;
      phosphate) (30 mg/m^2 x 3) and 2 gray (Gy) total body irradiation followed by human leukocyte&#xD;
      antigens (HLA) matched allogeneic hematopoietic transplantation for patients with relapsed or&#xD;
      refractory aggressive B-cell lymphoma.&#xD;
&#xD;
      OUTLINE:&#xD;
&#xD;
      Beginning 24-48 hours prior to therapy infusion, patients receive rituximab intravenously&#xD;
      (IV) over 4-6 hours and then receive a therapy-dose of high-dose yttrium Y 90 ibritumomab&#xD;
      tiuxetan IV over 30 minutes on day -14 prior to transplant. Patients also receive fludarabine&#xD;
      phosphate IV on days -4 to -2 and undergo TBI followed by allogeneic PBSCT on day 0. Patients&#xD;
      also receive cyclosporine orally (PO) twice daily (BID) on days -3 to 56 with taper to day&#xD;
      180 (related donor) or -3 to 100 with taper over 11 weeks (unrelated donor) and mycophenolate&#xD;
      mofetil PO BID on days 0-27 (related donor) or PO thrice daily (TID) on days 0-40 with taper&#xD;
      to day 96 (unrelated donor).&#xD;
&#xD;
      After completion of study treatment and assessments through ~day 100 following transplant,&#xD;
      patients are followed up at 1, 3, 6, and 12 months and then annually up to 2 years&#xD;
      thereafter.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Terminated due to insufficient funding&#xD;
  </why_stopped>
  <start_date type="Actual">November 16, 2011</start_date>
  <completion_date type="Actual">May 6, 2020</completion_date>
  <primary_completion_date type="Actual">May 6, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-free Survival</measure>
    <time_frame>1 year</time_frame>
    <description>Based on a one-sample chi-square test with one-sided significance level of five percent. This study will be deemed successful if the 1 year progression-free survival of this highest-risk group of patients is 54% or greater.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Absolute Neutrophil Count (ANC) Engraftment</measure>
    <time_frame>Up to day 100</time_frame>
    <description>The median time in days to achieve ANC recovery defined as ANC&gt;500uL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>Up to 2 years post transplant</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response Rates</measure>
    <time_frame>Day 100</time_frame>
    <description>Response is defined as having achieved a Partial Response or better.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment-related Mortality</measure>
    <time_frame>Day 100</time_frame>
    <description>Defined as death in the absence of progressive lymphoma that can be possibly, probably, or definitely attributed to the radioimmunotherapy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Platelet Engraftment</measure>
    <time_frame>Up to day 100</time_frame>
    <description>The median time in days to achieve platelet recovery as defined as platelet &gt;20,000uL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hematopoietic Toxicity</measure>
    <time_frame>Up to day 100</time_frame>
    <description>Clinical sequelae due to hematopoietic toxicity as defined by incidences of neutropenic fever and bleeding.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Post-Transplant Lymphoproliferative Disorder</condition>
  <condition>Recurrent Adult Diffuse Large Cell Lymphoma</condition>
  <condition>Recurrent B-Cell Non-Hodgkin Lymphoma</condition>
  <condition>Recurrent Burkitt Lymphoma</condition>
  <condition>Refractory B-Cell Non-Hodgkin Lymphoma</condition>
  <condition>Refractory Burkitt Lymphoma</condition>
  <condition>Refractory Diffuse Large B-Cell Lymphoma</condition>
  <arm_group>
    <arm_group_label>Treatment (radiolabeled antibody, TBI, allogeneic PBSCT)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Beginning 24-48 hours prior to therapy infusion, patients receive rituximab IV over 4-6 hours and then receive a therapy-dose of high-dose yttrium Y 90 ibritumomab tiuxetan IV over 30 minutes on day -14 prior to transplant. Patients also receive fludarabine phosphate IV on days -4 to -2 and undergo TBI followed by allogeneic PBSCT on day 0. Patients also receive cyclosporine PO BID on days -3 to 56 with taper to day 180 (related donor) or -3 to 100 with taper over 11 weeks (unrelated donor) and mycophenolate mofetil PO BID on days 0-27 (related donor) or PO TID on days 0-40 with taper to day 96 (unrelated donor).</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Allogeneic Hematopoietic Stem Cell Transplantation</intervention_name>
    <description>Undergo allogeneic PBSCT (infusion of donor stem cells via central catheter)</description>
    <arm_group_label>Treatment (radiolabeled antibody, TBI, allogeneic PBSCT)</arm_group_label>
    <other_name>allogeneic stem cell transplantation</other_name>
    <other_name>HSC</other_name>
    <other_name>HSCT</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclosporine</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Treatment (radiolabeled antibody, TBI, allogeneic PBSCT)</arm_group_label>
    <other_name>27-400</other_name>
    <other_name>Ciclosporin</other_name>
    <other_name>CsA</other_name>
    <other_name>Cyclosporin</other_name>
    <other_name>Cyclosporin A</other_name>
    <other_name>Gengraf</other_name>
    <other_name>Neoral</other_name>
    <other_name>OL 27-400</other_name>
    <other_name>Sandimmun</other_name>
    <other_name>Sandimmune</other_name>
    <other_name>SangCya</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fludarabine Phosphate</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (radiolabeled antibody, TBI, allogeneic PBSCT)</arm_group_label>
    <other_name>2-F-ara-AMP</other_name>
    <other_name>9H-Purin-6-amine, 2-fluoro-9-(5-O-phosphono-.beta.-D-arabinofuranosyl)-</other_name>
    <other_name>Beneflur</other_name>
    <other_name>Fludara</other_name>
    <other_name>SH T 586</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Indium In-111 Ibritumomab Tiuxetan</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (radiolabeled antibody, TBI, allogeneic PBSCT)</arm_group_label>
    <other_name>IDEC In2B8</other_name>
    <other_name>IDEC-In2B8</other_name>
    <other_name>In 111 Ibritumomab Tiuxetan</other_name>
    <other_name>In 111 Zevalin</other_name>
    <other_name>indium In 111 ibritumomab tiuxetan</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mycophenolate Mofetil</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Treatment (radiolabeled antibody, TBI, allogeneic PBSCT)</arm_group_label>
    <other_name>Cellcept</other_name>
    <other_name>MMF</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Pharmacological Study</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Treatment (radiolabeled antibody, TBI, allogeneic PBSCT)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Rituximab</intervention_name>
    <description>Given IV prior to yttrium Y 90 ibritumomab tiuxetan</description>
    <arm_group_label>Treatment (radiolabeled antibody, TBI, allogeneic PBSCT)</arm_group_label>
    <other_name>ABP 798</other_name>
    <other_name>BI 695500</other_name>
    <other_name>C2B8 Monoclonal Antibody</other_name>
    <other_name>Chimeric Anti-CD20 Antibody</other_name>
    <other_name>CT-P10</other_name>
    <other_name>IDEC-102</other_name>
    <other_name>IDEC-C2B8</other_name>
    <other_name>IDEC-C2B8 Monoclonal Antibody</other_name>
    <other_name>MabThera</other_name>
    <other_name>Monoclonal Antibody IDEC-C2B8</other_name>
    <other_name>PF-05280586</other_name>
    <other_name>Rituxan</other_name>
    <other_name>Rituximab Biosimilar ABP 798</other_name>
    <other_name>Rituximab Biosimilar BI 695500</other_name>
    <other_name>Rituximab Biosimilar CT-P10</other_name>
    <other_name>Rituximab Biosimilar PF-05280586</other_name>
    <other_name>Rituximab Biosimilar RTXM83</other_name>
    <other_name>Rituximab Biosimilar SAIT101</other_name>
    <other_name>RTXM83</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Total-Body Irradiation</intervention_name>
    <description>Undergo TBI</description>
    <arm_group_label>Treatment (radiolabeled antibody, TBI, allogeneic PBSCT)</arm_group_label>
    <other_name>TOTAL BODY IRRADIATION</other_name>
    <other_name>Whole-Body Irradiation</other_name>
    <other_name>TBI</other_name>
    <other_name>Whole Body Irradiation</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Yttrium Y-90 Ibritumomab Tiuxetan</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (radiolabeled antibody, TBI, allogeneic PBSCT)</arm_group_label>
    <other_name>IDEC-Y2B8</other_name>
    <other_name>IDEC-Y2B8 monoclonal antibody</other_name>
    <other_name>Y 90 Ibritumomab Tiuxetan</other_name>
    <other_name>Y 90 Zevalin</other_name>
    <other_name>Yttrium Y 90 Ibritumomab Tiuxetan</other_name>
    <other_name>yttrium Y90 ibritumomab tiuxetan</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fludarabine</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (radiolabeled antibody, TBI, allogeneic PBSCT)</arm_group_label>
    <other_name>118218</other_name>
    <other_name>2-Fluoro-9-beta-arabinofuranosyladenine</other_name>
    <other_name>2-Fluorovidarabine</other_name>
    <other_name>9-Beta-D-arabinofuranosyl-2-fluoro-9H-purin-6-amine</other_name>
    <other_name>Fluradosa</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients must have a histologically confirmed diagnosis of aggressive B-cell lymphoma&#xD;
             (diffuse large B-cell lymphoma [DLBCL], Burkitt lymphoma [BL], etc.) expressing the&#xD;
             CD20 antigen and have failed at least one prior standard systemic therapy&#xD;
&#xD;
          -  Patients must have relapsed after high-dose therapy and autologous transplantation or&#xD;
             be ineligible for high-dose therapy and autologous transplantation; patients that have&#xD;
             failed autologous transplantation are those with persistent disease &gt; 30 days after&#xD;
             transplant; those ineligible for autologous transplant include those with&#xD;
             chemoresistant disease (i.e., patients who have not achieved a partial response or&#xD;
             better with their most recent chemotherapy regimen), are expected to have a poor&#xD;
             outcome from autologous transplant (e.g., DLBCL relapsing within one year of&#xD;
             rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine sulfate,&#xD;
             prednisone [R-CHOP]-like chemotherapy, double hit lymphoma, v-myc myelocytomatosis&#xD;
             viral oncogene homolog (avian) positive [MYC+] lymphoma, persistent positron emission&#xD;
             tomography [PET] positivity after chemotherapy), are unable to collect sufficient or&#xD;
             tumor-free autologous stem cells per Seattle Cancer Care Alliance (SCCA) standard&#xD;
             practice, are unable to tolerate the high-dose autologous conditioning regimens, or&#xD;
             who refuse a high-dose autologous transplant regimen&#xD;
&#xD;
          -  Creatinine (Cr) &lt; 2.0&#xD;
&#xD;
          -  Bilirubin &lt; 1.5 mg/dL with the exception of patients thought to have Gilbert's&#xD;
             syndrome, who may have a total bilirubin above 1.5 mg/dL&#xD;
&#xD;
          -  Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) &lt; 3 x upper limit of&#xD;
             normal (ULN)&#xD;
&#xD;
          -  Patients must have an expected survival without treatment of &gt; 60 days and must be&#xD;
             free of major infection including human immunodeficiency virus (HIV)&#xD;
&#xD;
          -  Patients must have an HLA-identical related or HLA-matched unrelated donor&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Receipt of systemic anti-lymphoma therapy withinthe following intervals prior to the&#xD;
             therapeutic 90Y-ibritumomab tiuxetan dose:&#xD;
&#xD;
               -  &lt; 30 days for intravenously-administered cytotoxic chemotherapy and/or monoclonal&#xD;
                  antibodies&#xD;
&#xD;
               -  &lt; 5 half-lives for all other anti-cancer agents (e.g., targeted therapies,&#xD;
                  corticosteroids, immunomodulatory agents, etc.)&#xD;
&#xD;
          -  Inability to understand or give an informed consent&#xD;
&#xD;
          -  Active central nervous system lymphoma&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Fertile men or women unwilling to use contraceptive techniques during and for 12&#xD;
             months following treatment&#xD;
&#xD;
          -  Southwest Oncology Group (SWOG)/Eastern Cooperative Oncology Group (ECOG) performance&#xD;
             score &gt;= 2&#xD;
&#xD;
          -  High-dose chemotherapy or external beam radiation therapy to lung, liver, or kidneys &gt;&#xD;
             20 Gy within the previous 100 days prior to therapeutic 90Y-ibritumomab tiuxetan dose&#xD;
&#xD;
          -  Medical condition that would contraindicate allogeneic transplantation as per standard&#xD;
             practice guidelines (e.g., impaired cardiopulmonary function, hepatitis, etc)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ajay Gopal</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fred Hutch/University of Washington Cancer Consortium</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Fred Hutch/University of Washington Cancer Consortium</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>July 26, 2011</study_first_submitted>
  <study_first_submitted_qc>September 14, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 15, 2011</study_first_posted>
  <results_first_submitted>April 30, 2021</results_first_submitted>
  <results_first_submitted_qc>April 30, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">May 25, 2021</results_first_posted>
  <last_update_submitted>July 16, 2021</last_update_submitted>
  <last_update_submitted_qc>July 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 20, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Fred Hutchinson Cancer Research Center</investigator_affiliation>
    <investigator_full_name>Ajay Gopal</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Burkitt Lymphoma</mesh_term>
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
    <mesh_term>Lymphoma, B-Cell</mesh_term>
    <mesh_term>Lymphoma, Large B-Cell, Diffuse</mesh_term>
    <mesh_term>Lymphoproliferative Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vidarabine</mesh_term>
    <mesh_term>Cyclosporine</mesh_term>
    <mesh_term>Mycophenolic Acid</mesh_term>
    <mesh_term>Rituximab</mesh_term>
    <mesh_term>Antineoplastic Agents, Immunological</mesh_term>
    <mesh_term>Fludarabine</mesh_term>
    <mesh_term>Fludarabine phosphate</mesh_term>
    <mesh_term>Antibodies</mesh_term>
    <mesh_term>Immunoglobulins</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
    <mesh_term>Cyclosporins</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>May 7, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/72/NCT01434472/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Treatment (Radiolabeled Antibody, TBI, Allogeneic PBSCT)</title>
          <description>Beginning 24-48 hours prior to therapy infusion, patients receive rituximab IV over 4-6 hours and then receive a therapy-dose of high-dose yttrium Y 90 ibritumomab tiuxetan IV over 30 minutes on day -14 prior to transplant. Patients also receive fludarabine phosphate IV on days -4 to -2 and undergo TBI followed by allogeneic PBSCT on day 0. Patients also receive cyclosporine PO BID on days -3 to 56 with taper to day 180 (related donor) or -3 to 100 with taper over 11 weeks (unrelated donor) and mycophenolate mofetil PO BID on days 0-27 (related donor) or PO TID on days 0-40 with taper to day 96 (unrelated donor).&#xD;
Allogeneic Hematopoietic Stem Cell Transplantation: Undergo allogeneic PBSCT (infusion of donor stem cells via central catheter)&#xD;
Cyclosporine: Given PO&#xD;
Fludarabine Phosphate: Given IV&#xD;
Indium In-111 Ibritumomab Tiuxetan: Given IV&#xD;
Mycophenolate Mofetil: Given PO&#xD;
Pharmacological Study: Correlative studies&#xD;
Rituximab: Given IV prior to yttrium Y 90 ibritumomab tiuxetan&#xD;
Total-Body Irradiation: Undergo TBI&#xD;
Yttrium Y-90 Ibritumomab Tiuxetan: Given IV&#xD;
Fludarabine: Given IV</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Treatment (Radiolabeled Antibody, TBI, Allogeneic PBSCT)</title>
          <description>Beginning 24-48 hours prior to therapy infusion, patients receive rituximab IV over 4-6 hours and then receive a therapy-dose of high-dose yttrium Y 90 ibritumomab tiuxetan IV over 30 minutes on day -14 prior to transplant. Patients also receive fludarabine phosphate IV on days -4 to -2 and undergo TBI followed by allogeneic PBSCT on day 0. Patients also receive cyclosporine PO BID on days -3 to 56 with taper to day 180 (related donor) or -3 to 100 with taper over 11 weeks (unrelated donor) and mycophenolate mofetil PO BID on days 0-27 (related donor) or PO TID on days 0-40 with taper to day 96 (unrelated donor).&#xD;
Allogeneic Hematopoietic Stem Cell Transplantation: Undergo allogeneic PBSCT (infusion of donor stem cells via central catheter)&#xD;
Cyclosporine: Given PO&#xD;
Fludarabine Phosphate: Given IV&#xD;
Indium In-111 Ibritumomab Tiuxetan: Given IV&#xD;
Mycophenolate Mofetil: Given PO&#xD;
Pharmacological Study: Correlative studies&#xD;
Rituximab: Given IV prior to yttrium Y 90 ibritumomab tiuxetan&#xD;
Total-Body Irradiation: Undergo TBI&#xD;
Yttrium Y-90 Ibritumomab Tiuxetan: Given IV&#xD;
Fludarabine: Given IV</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="20"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="52.5" lower_limit="36" upper_limit="66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Progression-free Survival</title>
        <description>Based on a one-sample chi-square test with one-sided significance level of five percent. This study will be deemed successful if the 1 year progression-free survival of this highest-risk group of patients is 54% or greater.</description>
        <time_frame>1 year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment (Radiolabeled Antibody, TBI, Allogeneic PBSCT)</title>
            <description>Beginning 24-48 hours prior to therapy infusion, patients receive rituximab IV over 4-6 hours and then receive a therapy-dose of high-dose yttrium Y 90 ibritumomab tiuxetan IV over 30 minutes on day -14 prior to transplant. Patients also receive fludarabine phosphate IV on days -4 to -2 and undergo TBI followed by allogeneic PBSCT on day 0. Patients also receive cyclosporine PO BID on days -3 to 56 with taper to day 180 (related donor) or -3 to 100 with taper over 11 weeks (unrelated donor) and mycophenolate mofetil PO BID on days 0-27 (related donor) or PO TID on days 0-40 with taper to day 96 (unrelated donor).&#xD;
Allogeneic Hematopoietic Stem Cell Transplantation: Undergo allogeneic PBSCT (infusion of donor stem cells via central catheter)&#xD;
Cyclosporine: Given PO&#xD;
Fludarabine Phosphate: Given IV&#xD;
Indium In-111 Ibritumomab Tiuxetan: Given IV&#xD;
Mycophenolate Mofetil: Given PO&#xD;
Pharmacological Study: Correlative studies&#xD;
Rituximab: Given IV prior to yttrium Y 90 ibritumomab tiuxetan&#xD;
Total-Body Irradiation: Undergo TBI&#xD;
Yttrium Y-90 Ibritumomab Tiuxetan: Given IV&#xD;
Fludarabine: Given IV</description>
          </group>
        </group_list>
        <measure>
          <title>Progression-free Survival</title>
          <description>Based on a one-sample chi-square test with one-sided significance level of five percent. This study will be deemed successful if the 1 year progression-free survival of this highest-risk group of patients is 54% or greater.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Absolute Neutrophil Count (ANC) Engraftment</title>
        <description>The median time in days to achieve ANC recovery defined as ANC&gt;500uL.</description>
        <time_frame>Up to day 100</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment (Radiolabeled Antibody, TBI, Allogeneic PBSCT)</title>
            <description>Beginning 24-48 hours prior to therapy infusion, patients receive rituximab IV over 4-6 hours and then receive a therapy-dose of high-dose yttrium Y 90 ibritumomab tiuxetan IV over 30 minutes on day -14 prior to transplant. Patients also receive fludarabine phosphate IV on days -4 to -2 and undergo TBI followed by allogeneic PBSCT on day 0. Patients also receive cyclosporine PO BID on days -3 to 56 with taper to day 180 (related donor) or -3 to 100 with taper over 11 weeks (unrelated donor) and mycophenolate mofetil PO BID on days 0-27 (related donor) or PO TID on days 0-40 with taper to day 96 (unrelated donor).&#xD;
Allogeneic Hematopoietic Stem Cell Transplantation: Undergo allogeneic PBSCT (infusion of donor stem cells via central catheter)&#xD;
Cyclosporine: Given PO&#xD;
Fludarabine Phosphate: Given IV&#xD;
Indium In-111 Ibritumomab Tiuxetan: Given IV&#xD;
Mycophenolate Mofetil: Given PO&#xD;
Pharmacological Study: Correlative studies&#xD;
Rituximab: Given IV prior to yttrium Y 90 ibritumomab tiuxetan&#xD;
Total-Body Irradiation: Undergo TBI&#xD;
Yttrium Y-90 Ibritumomab Tiuxetan: Given IV&#xD;
Fludarabine: Given IV</description>
          </group>
        </group_list>
        <measure>
          <title>Absolute Neutrophil Count (ANC) Engraftment</title>
          <description>The median time in days to achieve ANC recovery defined as ANC&gt;500uL.</description>
          <units>Days</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16" lower_limit="7" upper_limit="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Survival</title>
        <time_frame>Up to 2 years post transplant</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment (Radiolabeled Antibody, TBI, Allogeneic PBSCT)</title>
            <description>Beginning 24-48 hours prior to therapy infusion, patients receive rituximab IV over 4-6 hours and then receive a therapy-dose of high-dose yttrium Y 90 ibritumomab tiuxetan IV over 30 minutes on day -14 prior to transplant. Patients also receive fludarabine phosphate IV on days -4 to -2 and undergo TBI followed by allogeneic PBSCT on day 0. Patients also receive cyclosporine PO BID on days -3 to 56 with taper to day 180 (related donor) or -3 to 100 with taper over 11 weeks (unrelated donor) and mycophenolate mofetil PO BID on days 0-27 (related donor) or PO TID on days 0-40 with taper to day 96 (unrelated donor).&#xD;
Allogeneic Hematopoietic Stem Cell Transplantation: Undergo allogeneic PBSCT (infusion of donor stem cells via central catheter)&#xD;
Cyclosporine: Given PO&#xD;
Fludarabine Phosphate: Given IV&#xD;
Indium In-111 Ibritumomab Tiuxetan: Given IV&#xD;
Mycophenolate Mofetil: Given PO&#xD;
Pharmacological Study: Correlative studies&#xD;
Rituximab: Given IV prior to yttrium Y 90 ibritumomab tiuxetan&#xD;
Total-Body Irradiation: Undergo TBI&#xD;
Yttrium Y-90 Ibritumomab Tiuxetan: Given IV&#xD;
Fludarabine: Given IV</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Response Rates</title>
        <description>Response is defined as having achieved a Partial Response or better.</description>
        <time_frame>Day 100</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment (Radiolabeled Antibody, TBI, Allogeneic PBSCT)</title>
            <description>Beginning 24-48 hours prior to therapy infusion, patients receive rituximab IV over 4-6 hours and then receive a therapy-dose of high-dose yttrium Y 90 ibritumomab tiuxetan IV over 30 minutes on day -14 prior to transplant. Patients also receive fludarabine phosphate IV on days -4 to -2 and undergo TBI followed by allogeneic PBSCT on day 0. Patients also receive cyclosporine PO BID on days -3 to 56 with taper to day 180 (related donor) or -3 to 100 with taper over 11 weeks (unrelated donor) and mycophenolate mofetil PO BID on days 0-27 (related donor) or PO TID on days 0-40 with taper to day 96 (unrelated donor).&#xD;
Allogeneic Hematopoietic Stem Cell Transplantation: Undergo allogeneic PBSCT (infusion of donor stem cells via central catheter)&#xD;
Cyclosporine: Given PO&#xD;
Fludarabine Phosphate: Given IV&#xD;
Indium In-111 Ibritumomab Tiuxetan: Given IV&#xD;
Mycophenolate Mofetil: Given PO&#xD;
Pharmacological Study: Correlative studies&#xD;
Rituximab: Given IV prior to yttrium Y 90 ibritumomab tiuxetan&#xD;
Total-Body Irradiation: Undergo TBI&#xD;
Yttrium Y-90 Ibritumomab Tiuxetan: Given IV&#xD;
Fludarabine: Given IV</description>
          </group>
        </group_list>
        <measure>
          <title>Response Rates</title>
          <description>Response is defined as having achieved a Partial Response or better.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Treatment-related Mortality</title>
        <description>Defined as death in the absence of progressive lymphoma that can be possibly, probably, or definitely attributed to the radioimmunotherapy.</description>
        <time_frame>Day 100</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment (Radiolabeled Antibody, TBI, Allogeneic PBSCT)</title>
            <description>Beginning 24-48 hours prior to therapy infusion, patients receive rituximab IV over 4-6 hours and then receive a therapy-dose of high-dose yttrium Y 90 ibritumomab tiuxetan IV over 30 minutes on day -14 prior to transplant. Patients also receive fludarabine phosphate IV on days -4 to -2 and undergo TBI followed by allogeneic PBSCT on day 0. Patients also receive cyclosporine PO BID on days -3 to 56 with taper to day 180 (related donor) or -3 to 100 with taper over 11 weeks (unrelated donor) and mycophenolate mofetil PO BID on days 0-27 (related donor) or PO TID on days 0-40 with taper to day 96 (unrelated donor).&#xD;
Allogeneic Hematopoietic Stem Cell Transplantation: Undergo allogeneic PBSCT (infusion of donor stem cells via central catheter)&#xD;
Cyclosporine: Given PO&#xD;
Fludarabine Phosphate: Given IV&#xD;
Indium In-111 Ibritumomab Tiuxetan: Given IV&#xD;
Mycophenolate Mofetil: Given PO&#xD;
Pharmacological Study: Correlative studies&#xD;
Rituximab: Given IV prior to yttrium Y 90 ibritumomab tiuxetan&#xD;
Total-Body Irradiation: Undergo TBI&#xD;
Yttrium Y-90 Ibritumomab Tiuxetan: Given IV&#xD;
Fludarabine: Given IV</description>
          </group>
        </group_list>
        <measure>
          <title>Treatment-related Mortality</title>
          <description>Defined as death in the absence of progressive lymphoma that can be possibly, probably, or definitely attributed to the radioimmunotherapy.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Platelet Engraftment</title>
        <description>The median time in days to achieve platelet recovery as defined as platelet &gt;20,000uL.</description>
        <time_frame>Up to day 100</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment (Radiolabeled Antibody, TBI, Allogeneic PBSCT)</title>
            <description>Beginning 24-48 hours prior to therapy infusion, patients receive rituximab IV over 4-6 hours and then receive a therapy-dose of high-dose yttrium Y 90 ibritumomab tiuxetan IV over 30 minutes on day -14 prior to transplant. Patients also receive fludarabine phosphate IV on days -4 to -2 and undergo TBI followed by allogeneic PBSCT on day 0. Patients also receive cyclosporine PO BID on days -3 to 56 with taper to day 180 (related donor) or -3 to 100 with taper over 11 weeks (unrelated donor) and mycophenolate mofetil PO BID on days 0-27 (related donor) or PO TID on days 0-40 with taper to day 96 (unrelated donor).&#xD;
Allogeneic Hematopoietic Stem Cell Transplantation: Undergo allogeneic PBSCT (infusion of donor stem cells via central catheter)&#xD;
Cyclosporine: Given PO&#xD;
Fludarabine Phosphate: Given IV&#xD;
Indium In-111 Ibritumomab Tiuxetan: Given IV&#xD;
Mycophenolate Mofetil: Given PO&#xD;
Pharmacological Study: Correlative studies&#xD;
Rituximab: Given IV prior to yttrium Y 90 ibritumomab tiuxetan&#xD;
Total-Body Irradiation: Undergo TBI&#xD;
Yttrium Y-90 Ibritumomab Tiuxetan: Given IV&#xD;
Fludarabine: Given IV</description>
          </group>
        </group_list>
        <measure>
          <title>Platelet Engraftment</title>
          <description>The median time in days to achieve platelet recovery as defined as platelet &gt;20,000uL.</description>
          <units>Days</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9" lower_limit="0" upper_limit="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Hematopoietic Toxicity</title>
        <description>Clinical sequelae due to hematopoietic toxicity as defined by incidences of neutropenic fever and bleeding.</description>
        <time_frame>Up to day 100</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment (Radiolabeled Antibody, TBI, Allogeneic PBSCT)</title>
            <description>Beginning 24-48 hours prior to therapy infusion, patients receive rituximab IV over 4-6 hours and then receive a therapy-dose of high-dose yttrium Y 90 ibritumomab tiuxetan IV over 30 minutes on day -14 prior to transplant. Patients also receive fludarabine phosphate IV on days -4 to -2 and undergo TBI followed by allogeneic PBSCT on day 0. Patients also receive cyclosporine PO BID on days -3 to 56 with taper to day 180 (related donor) or -3 to 100 with taper over 11 weeks (unrelated donor) and mycophenolate mofetil PO BID on days 0-27 (related donor) or PO TID on days 0-40 with taper to day 96 (unrelated donor).&#xD;
Allogeneic Hematopoietic Stem Cell Transplantation: Undergo allogeneic PBSCT (infusion of donor stem cells via central catheter)&#xD;
Cyclosporine: Given PO&#xD;
Fludarabine Phosphate: Given IV&#xD;
Indium In-111 Ibritumomab Tiuxetan: Given IV&#xD;
Mycophenolate Mofetil: Given PO&#xD;
Pharmacological Study: Correlative studies&#xD;
Rituximab: Given IV prior to yttrium Y 90 ibritumomab tiuxetan&#xD;
Total-Body Irradiation: Undergo TBI&#xD;
Yttrium Y-90 Ibritumomab Tiuxetan: Given IV&#xD;
Fludarabine: Given IV</description>
          </group>
        </group_list>
        <measure>
          <title>Hematopoietic Toxicity</title>
          <description>Clinical sequelae due to hematopoietic toxicity as defined by incidences of neutropenic fever and bleeding.</description>
          <units>Incidences</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>AEs will be collected from the time of first exposure to a study intervention (i.e., the start of the rituximab infusion associated with the therapy dose) through day +100 post-transplant or through discharge prior to that date from the SCCA system to care of the patient's primary physician.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Treatment (Radiolabeled Antibody, TBI, Allogeneic PBSCT)</title>
          <description>Beginning 24-48 hours prior to therapy infusion, patients receive rituximab IV over 4-6 hours and then receive a therapy-dose of high-dose yttrium Y 90 ibritumomab tiuxetan IV over 30 minutes on day -14 prior to transplant. Patients also receive fludarabine phosphate IV on days -4 to -2 and undergo TBI followed by allogeneic PBSCT on day 0. Patients also receive cyclosporine PO BID on days -3 to 56 with taper to day 180 (related donor) or -3 to 100 with taper over 11 weeks (unrelated donor) and mycophenolate mofetil PO BID on days 0-27 (related donor) or PO TID on days 0-40 with taper to day 96 (unrelated donor).&#xD;
Allogeneic Hematopoietic Stem Cell Transplantation: Undergo allogeneic PBSCT (infusion of donor stem cells via central catheter)&#xD;
Cyclosporine: Given PO&#xD;
Fludarabine Phosphate: Given IV&#xD;
Indium In-111 Ibritumomab Tiuxetan: Given IV&#xD;
Mycophenolate Mofetil: Given PO&#xD;
Pharmacological Study: Correlative studies&#xD;
Rituximab: Given IV prior to yttrium Y 90 ibritumomab tiuxetan&#xD;
Total-Body Irradiation: Undergo TBI&#xD;
Yttrium Y-90 Ibritumomab Tiuxetan: Given IV&#xD;
Fludarabine: Given IV</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE (4.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal Pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Enterocolitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Wound Infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>E. coli bacteremia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Blood infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Neutropenic fever</sub_title>
                <counts group_id="E1" events="5" subjects_affected="3" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Acute Renal Injury</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Extrapyramidal disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Adenovirus pneumonia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>ARDS</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Ascites</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Thromboembolic event - cerebal infarct</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>CTCAE (4.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypophosphatemia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Ajay Gopal</name_or_title>
      <organization>Fred Hutchinson Cancer Research Center</organization>
      <phone>206-606-2037</phone>
      <email>agopal@uw.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

